Home  >  News
Marketing + Font Resize -

Ajanta Pharma gets launches generic Kapvay tablets in US market

Our Bureau, Mumbai
Wednesday, November 22, 2017, 13:30 Hrs  [IST]

After receiving US FDA approval for clonidine hydrochloride extended release tablets, Ajanta Pharma launched the product in 0.1 mg dosage in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Kapvay tablets and it has launched the product in 0.1mg dosage.

Clonidine hydrochloride extended release tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 39 ANDAs of which it has 22 final ANDA approvals, 2 tentative approval and 15 ANDAs under review with US FDA. Till date, it has launched 16 products in the US market.

Ajanta scrip moved up by Rs.6.65 to Rs.1,349.60 on BSE in the morning today. The scrip touched to yearly highest level at Rs.1,922 on December 8, 2016 and lowest level at Rs.1,106 on August 22, 2017.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CPhI-WW-Banners-150X60-120618-anim-v2
pharmalytica_150x60_2018
CPhI_MEA_Banner_150x60_2018
150X60px_biowavers
IPE_2018_Banner_150X60
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |